1. Home
  2. NIC vs ZYME Comparison

NIC vs ZYME Comparison

Compare NIC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nicolet Bankshares Inc.

NIC

Nicolet Bankshares Inc.

HOLD

Current Price

$129.31

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$26.64

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIC
ZYME
Founded
2000
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.0B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
NIC
ZYME
Price
$129.31
$26.64
Analyst Decision
Buy
Strong Buy
Analyst Count
3
9
Target Price
$145.33
$28.50
AVG Volume (30 Days)
121.4K
1.9M
Earning Date
01-20-2026
11-06-2025
Dividend Yield
0.99%
N/A
EPS Growth
18.84
N/A
EPS
9.34
N/A
Revenue
$375,962,000.00
$134,481,000.00
Revenue This Year
N/A
$64.45
Revenue Next Year
$5.09
$67.04
P/E Ratio
$13.88
N/A
Revenue Growth
9.68
116.21
52 Week Low
$97.90
$9.03
52 Week High
$141.92
$28.49

Technical Indicators

Market Signals
Indicator
NIC
ZYME
Relative Strength Index (RSI) 60.37 68.38
Support Level $124.79 $24.83
Resistance Level $130.39 $28.49
Average True Range (ATR) 2.91 1.57
MACD 0.96 0.15
Stochastic Oscillator 92.08 70.98

Price Performance

Historical Comparison
NIC
ZYME

About NIC Nicolet Bankshares Inc.

Nicolet Bankshares Inc is a United States-based bank holding company's principal business is banking, consisting of lending and deposit gathering, as well as ancillary banking-related products and services, to businesses and individuals of the communities it serves, and the operational support to deliver, fund and manage. It offers a variety of loans, deposits, and related services to business customers especially small and medium-sized businesses and professional concerns, business deposit products, cash management services, international banking services, business loans, lines of credit, commercial real estate financing, construction loans, agricultural real estate or production loans, and letters of credit, as well as retirement plan services.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: